


## KTIN Therapeutics

### Revolutionizing Sports Performance & Recovery | \$10M Series A

### Columbia University Startup | "The Next EPO" - Legal Performance Enhancement

#### Circulating osteocalcin surges during exercise in rodents and humans



## The Problem

Muscle injuries devastate athletic performance with **no effective recovery**

#### therapies:

- **30-50% of all sports injuries** are muscle-related (strains, contusions, tears)
- **Weeks of downtime** cost athletes millions in lost revenue
- **Racing horses & working dogs** face similar recovery challenges
- **Current solutions** (rest, ice, NSAIDs) are slow and ineffective

## Our Solution: IL-6–Osteocalcin Axis Innovation


### Three Products, Revolutionary Mechanism:

- **KTIN-100** (IM injection, 6-8 weeks): IL-6/bisphosphonate conjugate releases endogenous OCN
- **KTIN-200** (daily oral): Direct osteocalcin delivery
- **KTIN-300** (animal feed): Veterinary applications

## Breakthrough Preclinical Results:

- **30% improved exercise capacity** in mice (outperforming EPO)
- **30-50% faster recovery times** projected:
  - Hamstring strains: 2-3 weeks vs. 4 weeks
  - Contusions: 1-2 weeks vs. 3 weeks

KTIN-100: Exercise capacity in 10-months-old mice after i.p. injection of vehicle or IL6-BP



- Racehorse microtears: 2-3 days vs. 5-7 days

## Market Opportunity (\$90B+)

Segment	Market Size	Annual Spend	5% Capture
<b>Athletes</b> (Injury Prevention & Recovery)	\$15B	\$1,500/person	\$750M
<b>Aging</b> (Falls, Sarcopenia, Cachexia)	\$54B	\$900/person	\$2.7B
<b>Companion Animals</b> (Muscle Endurance)	\$3B	\$300/animal	\$150M
<b>Animal Recovery</b> (Horses, Working Dogs)	\$20B	\$1,000/animal	\$1B

**Total 5% Capture Opportunity: \$4.6B**

## Key Clinical Insight: Function Over Mass

### KTIN enhances muscle FUNCTION through:

- Improved ATP production and glucose uptake
- Enhanced mitochondrial efficiency
- Reduced inflammation and oxidative stress
- **Performance metrics improve faster than muscle size**

## Competitive Advantage

- ✓ **First-Mover:** Only IL-6–OCN axis therapy in development
- ✓ **World-Class Science:** Dr. Gerard Karsenty's 20+ years bone-muscle research
- ✓ **Strong IP:** Columbia University PCT application
- ✓ **Ethical Edge:** Legal alternative to EPO - safe performance enhancement
- ✓ **Dual Market:** Human athletes + veterinary sports applications

## Development Timeline & Revenue Path

### Fast Track to Market:

- **2026:** CMC completion, GLP studies (canine/horse models)
- **2026/7:** IND submission, regulatory approvals
- **2027/8:** Phase 1 trials (humans), veterinary market entry
- **Year 3-4:** \$10-20M veterinary revenue (racing horses, working dogs)
- **Year 6:** \$50-100M human athlete market

## Financial Projections

- **Veterinary Revenue:** \$10-20M by Year 3-4
- **Human Athletes:** \$50-100M by Year 6
- **Premium Pricing:** Elite athletes and racehorse owners pay premium for faster recovery
- **Exit Strategy:** Acquisition by sports medicine (Zimmer), aging pharma (AbbVie, Lilly), or veterinary (Zoetis, Elanco)
- **Target ROI:** 10x on \$10M investment

## Use of Funds (\$10M Series A)

- **\$4.0M** CMC Development (GL/MP manufacturing for KTIN-100)
- **\$1.5M** GLP Studies (canine/horse muscle recovery models)
- **\$3.5M** Phase 1 Human Trial (safety in athletes with muscle injuries)
- **\$0.5M** KTIN-200 final development
- **\$0.5M** R&D, regulatory, operations & team expansion

## Product Pipeline

Asset	Indication	Target	Route	Market
KTIN-100	Muscle injuries, fatigue	Gprc6a (myofibers)	IM	Athletes, aging
KTIN-200	Muscle injuries, metabolic	Gprc6a, PGC-1 $\alpha$	Oral	Athletes, aging
KTIN-300	Performance, recovery	Gprc6a, PGC-1 $\alpha$	Feed	Veterinary

## Leadership Team

- **Martin Dueñas, MPA** - CEO & Co-Founder (10+ years biotech startups)
- **Dr. Gerard Karsenty, MD, PhD** - CSO & Scientific Founder (Columbia University, world-renowned OCN expert)

## Strategic Partnerships

**Universities:** Columbia, Cornell, CIBERDEM Spain, INSERM

**CROs:** Altascienes, NorthEast Biolabs, Charles River Labs

**CDMOs:** KBI, Catalent, Lonza, Piramal

## Regulatory Strategy

- **Dual FDA Pathway:** CVM (animals) + CDER (humans)
- **<4-year veterinary timeline** for faster revenue generation
- **Clear path** to human athletic applications

**Contact:** Martin Dueñas, CEO | [martin@onixhub.com](mailto:martin@onixhub.com)

---

## Investment Thesis

### Why Invest Now:

- First-mover in \$90B+ sports performance market
- Proven 30% performance improvement in preclinical models
- Legal alternative to banned performance enhancers
- Fast veterinary revenue path (3-4 years) de-risks human development
- Premium pricing potential in elite sports markets

**The Opportunity:** Be part of the next breakthrough in legal sports performance enhancement

**Contact:** Martin Dueñas, CEO | [martin@onixhub.com](mailto:martin@onixhub.com)

*"Revolutionizing sports performance and recovery with KTIN-100/200 — your athletes and horses deserve the best"*